NASDAQ:DTIL Precision BioSciences Q1 2026 Earnings Results & Report $7.57 0.00 (0.00%) Closing price 11/13/2026 04:00 PM EasternExtended Trading$7.58 +0.00 (+0.07%) As of 03:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Precision BioSciences missed analyst earnings expectations but beat on revenue in its Q1 2026 results, released May 5, 2026. The company reported EPS of -$0.75 versus the -$0.6550 consensus estimate, while revenue of $10.84 million topped the $4.05 million estimate by $6.79 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2026Report DateMay 5, 2026TimeBefore Market OpensConference Call9:30 AM ET Precision BioSciences EPS ResultsActual EPS-$0.75Consensus EPS -$0.6550Beat/MissMissed by -$0.0950One Year Ago EPSN/AEPS Beat Rate2 of last 8 quartersPrecision BioSciences Revenue ResultsActual Revenue$10.84 millionExpected Revenue$4.05 millionBeat/MissBeat by +$6.79 millionYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Precision BioSciences Q1 2026 Earnings FAQ Did Precision BioSciences beat earnings estimates for Q1 2026? Precision BioSciences (NASDAQ:DTIL) reported earnings of -$0.75 per share for Q1 2026, missing the consensus estimate of -$0.6550. The report was announced on Tuesday, May 5, 2026. What was Precision BioSciences' revenue for Q1 2026? Precision BioSciences reported revenue of $10.84 million for Q1 2026, against a consensus estimate of $4.05 million. Precision BioSciences Earnings HeadlinesPrecision BioSciences, Inc. (DTIL) Discusses Phase 1 ELIMINATE-B Data for PBGENE-HBV in Chronic Hepatitis B TranscriptNovember 9, 2026 | seekingalpha.comHC Wainwright Has Bullish Estimate for DTIL FY2026 EarningsNovember 9, 2026 | americanbankingnews.comExecutive Order 14241 Unleashes Trump’s New DollarA landmark executive order, 14241, is reportedly set to reshape how Americans use money starting this December. The agenda at the upcoming G20 Summit in Miami has shifted, and new research points to a major monetary announcement from President Trump. A new documentary breaks down what this shift could mean for savings, investments, and the assets tied to it.November 16 at 1:00 AM | Porter & Company (Ad)Precision BioSciences (NASDAQ:DTIL) Upgraded to Hold at Wall Street ZenNovember 7, 2026 | americanbankingnews.comPrecision BioSciences prices 10.24M shares at $7.75 in underwritten offeringNovember 5, 2026 | finance.yahoo.comH.C. Wainwright Sticks to Their Buy Rating for Precision BioSciences (DTIL)November 4, 2026 | theglobeandmail.comSee More Precision BioSciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Precision BioSciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Precision BioSciences and other key companies, straight to your email. Email Address About Precision BioSciencesPrecision BioSciences (NASDAQ:DTIL) is a biotechnology company developing gene-editing therapies using its proprietary ARCUS platform. The platform is designed to make targeted changes to DNA and is being applied to investigational treatments for genetic and infectious diseases. The company’s programs include PBGENE-HBV, an investigational therapy designed to target hepatitis B virus DNA, and PBGENE-DMD, a gene-editing program for Duchenne muscular dystrophy. These candidates remain in development and are not approved treatments. Founded in 2006 and headquartered in Durham, North Carolina, Precision BioSciences has also pursued applications of its gene-editing technology through collaborations and licensing arrangements.View Precision BioSciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3 Building-Materials Stocks Rallying While Homebuilders Struggle to Find BuyersMarketBeat Week in Review – 11/9 - 11/13Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCerebras Q3 Results: How Much More Proof Does Wall Street Need?Applied Materials Beats and Raises, But Investors Stay Unconvinced3 Power and Grid Stocks That Could Keep Growing Even if AI Spending SlowsYETI Beat on Earnings, But Its Sales Tell a Different Story Upcoming Earnings Walt Disney (11/17/2026)Home Depot (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.